SEC Form 4 · accession 0001171843-17-006105
Protara Therapeutics, Inc. · TARA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy P Noyes
Officer — President and CEO · Director
Period of report
Oct 16, 2017
Accepted (ET)
Oct 17, 2017 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001359931
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 16, 2017 | D | 10,000 | $2.312 | D | 38,742 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017.
- F2The selling price of $2.312 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $2.25 to $2.35. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.